Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
OTAI$10.11+0.00(+0.05%)Spider Digital Technology Ltd. and Starlink AI Acquisition Corporation Announce Definitive Business Combination Agreement[6:30:00 PM ET]REVVF$0.170.00(0.00%)Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario[6:30:00 PM ET]CTSH$65.00+2.48(+3.97%)Cognizant setzt mehr als 25.000 Fachkräfte für die Umsetzung von OpenAI-Lösungen ein, während Unternehmen bahnbrechende KI-Technologien in die Produktion überführen Cognizant (Nasdaq: CTSH) gab heute die Gründung seiner „OpenAI Frontier Capability Group" bekannt, in der mehr als 25.000 Fachkräfte zusammenkommen,...[6:17:00 PM ET]INO$1.92+1.15(+148.83%)INOVIO Announces FDA Accelerated Approval of VOCERYQ™, an Immunotherapy to Reduce the Frequency of Surgery in Adults with Recurrent Respiratory Papillomatosis (RRP) INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from...[6:01:00 PM ET]KVUE$19.60+0.04(+0.20%)Okta Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400, S&P SmallCap 600 effective prior to the opening of trading on...[5:51:00 PM ET]ACET$3.42-0.16(-4.47%)Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)[5:38:00 PM ET]BKOR$31.900.00(0.00%)Oak Ridge Financial Services, Inc. Announces Third Quarter and Nine Months Ended September 30, 2026 Results and Quarterly Cash Dividend of $0.16 Per Common Share[5:32:47 PM ET]BHAVU$10.170.00(0.00%)BHAV Acquisition Corp II Announces Closing of $100 Million Initial Public Offering[5:30:00 PM ET]SABA$7.62-0.03(-0.39%)SABA Announces Notification of Sources of Distributions[5:30:00 PM ET]BRW$6.00+0.01(+0.17%)BRW Announces Notification of Sources of Distributions[5:30:00 PM ET]MUEL$416.00-6.00(-1.42%)Paul Mueller Company Announces Its Third Quarter Earnings of 2026[5:28:01 PM ET]NBRKF$0.13-0.00(-2.00%)New Break Announces $550,000 Non-Brokered Private Placement Offering of Flow-Through Shares[5:23:00 PM ET]FUJIY$10.98+0.06(+0.55%)Fujifilm to Increase Production Capacity by 5x for Magnetic Data Storage Tape[5:18:00 PM ET]ATNM$1.44-0.09(-5.88%)Actinium Pharmaceuticals Announces Inducement Grant to New Employee Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today...[5:15:00 PM ET]

ATNM · AMEX

Actinium Pharmaceuticals, Inc.

$1.44 -0.09 (-5.88%)

Company overview

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for bone marrow transplant (BMT) and other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B), is in a pivotal Phase III clinical trial for elderly patients with relapsed or refractory acute myeloid leukemia for BMT conditioning, and in a Phase I study with a CD19-targeted CAR T-cell therapy with Memorial Sloan Kettering Cancer Center.

Sector
Healthcare
Industry
Biotechnology
Exchange
AMEX
Market cap
$45.3M
Employees
31
Headquarters
New York City, NY
Website
actiniumpharma.com
CEO
Sandesh C. Seth
Listed
December 27, 2012
P/E
-1.92
Dividend yield
0.00%

Company financials

Revenue
$90,000
Gross profit
$485,000
Operating income
-$25.5M
EBITDA
-$24.7M
Net income
-$23.5M
EPS
-$0.75
Total assets
$45.4M
Total debt
$1.5M
Gross margin
538.89%
Net margin
-26,078.89%
Earnings yield
-52.08%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

No geographic segmentation.

Showing FY 2025

Price chart

0.700.951.201.451.70
ATNM 1D AMEX O1.38H1.56L1.38C1.53+0.15 (+10.87%)Vol181.67K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Announces Inducement Grant to New Employee Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today... PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals to Highlight First-in-Human Phase 1 Study of ATNM-400 a HER3-Targeted Non-PSMA Radiotherapy in Prostate Cancer at ESMO 2026 Actinium Pharmaceuticals, Inc. PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Unveils ATNM‑400 Data at EANM 2026 with a First‑In‑Human HER3‑Targeted Radiotherapy Approach Beyond PSMA in Prostate Cancer Actinium Pharmaceuticals, Inc. PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Presents EANM 2026 Results Reinforcing ATNM-400's Pan-Tumor Potential Across Lung, Colorectal and Ovarian Cancer Models Actinium Pharmaceuticals, Inc. PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals to Showcase ATNM-400's First-in-Human Clinical Data in Prostate Cancer and Preclinical Results in Lung Cancer Supporting Pan-Tumor Potential Today at EANM 2026 Actinium Pharmaceuticals, Inc. PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Announces Inducement Grants to New Employees Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today... PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Announces Oral and Poster Presentations at EANM 2026 Highlighting Broad Antitumor Activity of ATNM-400 Across Lung, Colorectal and Ovarian Cancer Models Actinium Pharmaceuticals, Inc. PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Appoints Radiopharmaceutical Industry Veteran Sean Maenpaa as Senior Vice President, Business Development Actinium Pharmaceuticals, Inc. PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Announces Oral Presentation at EANM 2026 Highlighting First-in-Human Phase 1 Study of ATNM-400, a Non-PSMA Targeting Radiotherapy, in Prostate Cancer Actinium Pharmaceuticals, Inc. PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer Actinium Pharmaceuticals, Inc. PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update PRNewsWire
ATNMActinium Pharmaceuticals, Inc. Stock news Palatin Technologies (OTCMKTS:PTNT) and Actinium Pharmaceuticals (NYSE:ATNM) Head to Head Review Defense World
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer PRNewsWire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models PRNewsWire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development PRNewsWire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates PRNewsWire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs PRNewsWire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice PRNewsWire
ATNMActinium Pharmaceuticals, Inc. Press release Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization PRNewsWire
See more
FAQ

Questions about Actinium Pharmaceuticals, Inc.

What does Actinium Pharmaceuticals, Inc. do?
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for bone marrow transplant (BMT) and other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B), is in a pivotal Phase III clinical trial for elderly patients with relapsed or refractory acute myeloid leukemia for BMT conditioning, and in a Phase I study with a CD19-targeted CAR T-cell therapy with Memorial Sloan Kettering Cancer Center.
What is ATNM's market cap?
Actinium Pharmaceuticals, Inc. (ATNM) is a listed stock with a live quote. The latest market cap on this page is $45.3M.
Where is Actinium Pharmaceuticals, Inc. headquartered?
Actinium Pharmaceuticals, Inc. is headquartered in New York City, NY.
How do I get ATNM news from the API?
Call GET /v1/news?tickers=ATNM. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does ATNM news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for ATNM, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the ATNM price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs